2023
Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
Velez J, Karakala N, Tayebi K, Wickman T, Mohamed M, Kovacic R, Therapondos G, Kanduri S, Allegretti A, Belcher J, Regner K, Wentowski C. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1. Kidney360 2023, 4: e448-e456. PMID: 36763632, PMCID: PMC10278824, DOI: 10.34067/kid.0000000000000068.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Mean arterial pressureSyndrome type 1HRS-1Baseline SCrMAP riseType 1Serum creatinineArterial pressureKidney functionDay 14Baseline mean arterial pressureMean mean arterial pressureMedian mean arterial pressureEnd-stage liver diseaseMultivariate logistic regression analysisFavorable renal outcomeOptimal MAP targetsUse of norepinephrineLogistic regression analysisGreater reductionMedian sCrNorepinephrine useVasoconstrictor therapyRenal outcomes
2015
Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis
Belcher JM, Coca SG, Parikh CR. Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis. PLOS ONE 2015, 10: e0135625. PMID: 26295585, PMCID: PMC4546623, DOI: 10.1371/journal.pone.0135625.Peer-Reviewed Original ResearchConceptsDelta creatinineHepatorenal syndromeRelative riskSerum creatininePost-treatment mortalityVasoconstrictor therapyRandomized trialsHRS type 1Completion of treatmentWeb of ScienceRenal functionCreatinine changesOverall mortalitySevere complicationsControl armTreatment periodVasoconstrictor medicationCreatinineElectronic databasesMeta-AnalysisSystematic reviewMortalityType 1PatientsSignificant mortality